2-(4-硝基苯基)丙烷-1,1,3,3-四羧酸四乙酯 | 126989-14-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(4-硝基苯基)丙烷-1,1,3,3-四羧酸四乙酯
• 英文名称: tetraethyl 2-(4-nitrophenyl)propane-1,1,3,3-tetracarboxylate
• 英文别名: 2,4-bis-ethoxycarbonyl-3-(4-nitrophenyl)pentanedioic acid diethyl ester；2-(4-nitro-phenyl)-propane-1,1,3,3-tetracarboxylic acid tetraethyl ester；4-Nitro-benzal-dimalonsaeure-tetraaethylester；2-(4-Nitro-phenyl)-propan-1,1,3,3-tetracarbonsaeure-tetraaethylester；β-(4-Nitro-phenyl)-α.α'-dicarboxy-glutarsaeure-tetraaethylester
• CAS: 126989-14-8
• 化学式: C₂₁H₂₇NO₁₀
• 分子量: 453.446
• InChiKey: SGYUBTVCLVPOCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  32
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  151
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  2-(4-硝基苯基)丙烷-1,1,3,3-四羧酸四乙酯 在 盐酸 、 tin(ll) chloride 作用下， 生成 3-(4-amino-phenyl)-glutaric acid
  参考文献：
  名称：

  Koetz, Journal fur praktische Chemie (Leipzig 1954), 1907, vol. <2> 75, p. 508

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(4-硝基亚苄基)丙二酸二乙酯 在 sodium ethanolate 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 6.41h， 以93%的产率得到2-(4-硝基苯基)丙烷-1,1,3,3-四羧酸四乙酯
  参考文献：
  名称：

  INHIBITORS OF C-FMS KINASE

  摘要：

  本发明涉及式I化合物：其中Z、X、J、R2和W在说明书中规定，以及抑制蛋白酪氨酸激酶，尤其是c-fms激酶的溶剂化物、水合物、互变异构体和药用盐。治疗自身免疫病；和治疗具有炎症成分的疾病；治疗来自卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病的转移；和治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症性和神经性疼痛；以及骨质疏松症、佩吉特病，以及骨吸收介导病状的其它疾病，包括类风湿性关节炎、其它形式的炎症性关节炎、骨关节炎、假体失败、溶骨肉瘤、骨髓瘤和骨转移瘤，也提供了式I化合物。

  公开号：

  US20070249593A1

文献信息

• Lewis acidic ionic liquids for the synthesis of electrophilic alkenes via the Knoevenagel condensation
  作者：Jitendra R Harjani、Susheel J Nara、Manikrao M Salunkhe

  DOI：10.1016/s0040-4039(01)02341-3

  日期：2002.2

  [bpy]Cl·AlCl3, N=0.67 ionic liquids were found to work well as the Lewis acid catalyst and solvent in the Knoevenagel condensations of benzaldehyde and substituted benzaldehydes with diethyl malonate to give benzylidene malonates. The benzylidene malonates subsequently underwent Michael additions with diethyl malonate. The extent of Michael product formed during the reaction was found to vary with the Lewis acidity

  1-丁基-3-甲基咪唑鎓氯铝酸盐，[bmim] Cl·AlCl 3，N = 0.67和1-丁基吡啶鎓氯铝酸盐，[bpy] Cl·AlCl 3，N发现＝ 0.67离子液体在苯甲醛和取代的苯甲醛与丙二酸二乙酯的Knoevenagel缩合反应中作为路易斯酸催化剂和溶剂很好地工作，得到亚苄基丙二酸酯。亚苄基丙二酸酯随后与丙二酸二乙酯进行迈克尔加成。发现反应过程中迈克尔产物的形成程度随路易斯酸度和离子液体的摩尔比而变化。证明了离子液体的路易斯酸度对Knoevenagel和Michael产品的影响。在2-羟基芳基醛的情况下，该反应导致在环境条件下形成3-乙氧基羰基香豆素。
• Inhibitors of C-FMS Kinase
  申请人：Illig Carl R.

  公开号：US20080275031A1

  公开（公告）日：2008-11-06

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及公式I的化合物：其中Z，X，J，R2和W在规范中设置，以及其溶剂化物，水合物，互变异构体和药学上可接受的盐，该化合物抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用公式I化合物治疗自身免疫性疾病和具有炎症成分的疾病的方法；治疗卵巢癌，子宫癌，乳腺癌，前列腺癌，肺癌，结肠癌，胃癌，毛细胞白血病的转移；以及治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或脏器，炎症和神经源性疼痛；以及骨质疏松症，帕吉特氏病和其他骨吸收介导发病率的疾病，包括类风湿性关节炎和其他形式的炎性关节炎，骨关节炎，假体失败，骨溶性肉瘤，骨髓瘤和肿瘤转移至骨骼的公式I化合物。
• Inhibitors of c-fms kinase
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US07414050B2

  公开（公告）日：2008-08-19

  The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及一类式I的化合物：其中Z、X、J、R2和W在规范中列出，以及其溶剂化物、水合物、互变异构体和药学上可接受的盐，该化合物抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用式I化合物治疗自身免疫性疾病和具有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病引起的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经性疼痛；以及骨质疏松症、帕吉特病和其他骨吸收介导的疾病，包括类风湿性关节炎和其他形式的炎症性关节炎、骨关节炎、假体失效、骨溶性肉瘤、骨髓瘤和转移至骨骼的肿瘤。
• Inhibitors of C-FMS kinase
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US07973035B2

  公开（公告）日：2011-07-05

  The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及式I的化合物：其中Z、X、J、R2和W在规范中列出，以及其溶剂化物、水合物、互变异构体和药学上可接受的盐，其抑制蛋白酪氨酸激酶，尤其是c-fms激酶。本发明还提供了使用式I化合物治疗自身免疫性疾病和带有炎症成分的疾病的方法；治疗卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经源性疼痛；以及骨质疏松症、帕吉特病和其他骨吸收介导的疾病，包括类风湿性关节炎和其他形式的炎症性关节炎、骨关节炎、假体失效、骨溶性肉瘤、骨髓瘤和转移至骨骼的肿瘤。
• A convenient one-pot synthesis, theoretical studies, and NMR-based conformational analysis of nitroarylidene dimalonates
  作者：Leman Alkan、Özgür Alver、Stephen T. Astley、Eralp Kulan、Cemal Parlak

  DOI：10.1016/j.molstruc.2022.133848

  日期：2022.12

  Tandem Knoevenagel-Michael addition of diethyl malonate to nitro-substituted benzaldehydes was found to proceed in a mild and convenient process. The 1H NMR spectra of the products showed significant changes according to the position of the nitro group. Conformational analysis calculations confirmed that in all cases, a structure containing a mirror plane occurred at energies near the ground state

  发现丙二酸二乙酯与硝基取代的苯甲醛的串联 Knoevenagel-Michael 加成过程温和且方便。产物的1 H NMR 光谱显示出根据硝基位置的显着变化。构象分析计算证实，在所有情况下，包含镜面的结构出现在接近基态的能量处。然而，对于间位和邻位取代的产物，增加的空间拥挤导致乙基取代基的旋转自由度降低。与空间应力增加的观察结果一致，分子轨道计算预测邻硝基取代产物的亲电反应性更高。